252 related articles for article (PubMed ID: 20798235)
1. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.
Kumar S; Dispenzieri A; Katzmann JA; Larson DR; Colby CL; Lacy MQ; Hayman SR; Buadi FK; Leung N; Zeldenrust SR; Ramirez-Alvarado M; Clark RJ; Kyle RA; Rajkumar SV; Gertz MA
Blood; 2010 Dec; 116(24):5126-9. PubMed ID: 20798235
[TBL] [Abstract][Full Text] [Related]
2. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
[TBL] [Abstract][Full Text] [Related]
3. [The prognostic value of baseline serum free light chain in immunoglobulin light-chain cardiac amyloidosis].
Wang LM; Wang TT; Tian Y; Zhao L; Yang XC; Chen WM
Zhonghua Xue Ye Xue Za Zhi; 2020 Jan; 41(1):47-53. PubMed ID: 32023754
[No Abstract] [Full Text] [Related]
4. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome.
Milani P; Basset M; Russo F; Foli A; Merlini G; Palladini G
Blood; 2017 Aug; 130(5):625-631. PubMed ID: 28546143
[TBL] [Abstract][Full Text] [Related]
5. [The diagnostic and prognostic values of serum free light chain in patients with primary light chain amyloidosis].
Zhang CL; Feng J; Shen KN; Su W; Zhang CL; Huang XF; Cao XX; Zhang L; Zhou DB; Li J
Zhonghua Xue Ye Xue Za Zhi; 2016 Nov; 37(11):942-945. PubMed ID: 27995877
[TBL] [Abstract][Full Text] [Related]
6. [The prognostic value of baseline serum free light chain in cardiac amyloidosis].
Zhao L; Tian Z; Fang Q
Zhonghua Nei Ke Za Zhi; 2016 Mar; 55(3):186-90. PubMed ID: 26926369
[TBL] [Abstract][Full Text] [Related]
7. Amino acid sequence homology of monoclonal serum free light chain dimers and tissue deposited light chains in AL amyloidosis: a pilot study.
Goldis R; Kaplan B; Arad M; Dispenzieri A; Dasari S; Kukuy OL; Simon AJ; Dori A; Shavit-Stein E; Ziv T; Murray D; Kourelis T; Gertz MA; Dominissini D; Magen H; Muchtar E
Clin Chem Lab Med; 2024 Feb; 62(3):464-471. PubMed ID: 37747270
[TBL] [Abstract][Full Text] [Related]
8. Impact of light chain isotype on clinical features and outcomes in systemic AL amyloidosis.
Hopson MB; Bhutani D; Sarkaria S; Maurer MS; Griffin JM; Mapara M; Lentzsch S; Chakraborty R
Leuk Lymphoma; 2022 Sep; 63(9):2109-2113. PubMed ID: 35465769
[TBL] [Abstract][Full Text] [Related]
9. A patient with AL amyloidosis with negative free light chain results.
Milani P; Valentini V; Ferraro G; Basset M; Russo F; Foli A; Palladini G; Merlini G
Clin Chem Lab Med; 2016 Jun; 54(6):1035-7. PubMed ID: 26677890
[TBL] [Abstract][Full Text] [Related]
10. Immunoglobulin-related (AL) amyloidosis.
Husby G
Clin Exp Rheumatol; 1983; 1(4):353-8. PubMed ID: 6442636
[TBL] [Abstract][Full Text] [Related]
11. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
[TBL] [Abstract][Full Text] [Related]
12. Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.
Sidana S; Tandon N; Dispenzieri A; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Kyle RA; Leung N; Go RS; Lust JA; Russell SJ; Zeldenrust SR; Rajkumar SV; Kumar SK
Leukemia; 2018 Mar; 32(3):729-735. PubMed ID: 28919633
[TBL] [Abstract][Full Text] [Related]
13. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.
Katzmann JA; Clark RJ; Abraham RS; Bryant S; Lymp JF; Bradwell AR; Kyle RA
Clin Chem; 2002 Sep; 48(9):1437-44. PubMed ID: 12194920
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis.
Matsuda M; Yamada T; Gono T; Shimojima Y; Ishii W; Fushimi T; Sakashita K; Koike K; Ikeda S
Intern Med; 2005 May; 44(5):428-33. PubMed ID: 15942088
[TBL] [Abstract][Full Text] [Related]
15. [Clinical presentation and prognosis in patients with light-chain amyloidosis with an ultra-high level of serum free light-chain].
Miao HL; Shen KN; Su W; Zhang L; Cao XX; Zhou DB; Li J
Zhonghua Xue Ye Xue Za Zhi; 2021 Mar; 42(3):199-204. PubMed ID: 33910304
[No Abstract] [Full Text] [Related]
16. Diagnostic approach to and follow-up of difficult cases of AL amyloidosis.
Perfetti V; Garini P; Vignarelli MC; Marinone MG; Zorzoli I; Merlini G
Haematologica; 1995; 80(5):409-15. PubMed ID: 8566880
[TBL] [Abstract][Full Text] [Related]
17. Capillary electrophoresis/immunosubtraction as a better alternative to immunofixation for detecting and immunotyping serum monoclonal proteins in patients with immunoglobulin light chain (AL) amyloidosis.
Miyazaki K; Suzuki K
Amyloid; 2016 Dec; 23(4):221-224. PubMed ID: 27682970
[TBL] [Abstract][Full Text] [Related]
18. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.
Dispenzieri A; Kyle R; Merlini G; Miguel JS; Ludwig H; Hajek R; Palumbo A; Jagannath S; Blade J; Lonial S; Dimopoulos M; Comenzo R; Einsele H; Barlogie B; Anderson K; Gertz M; Harousseau JL; Attal M; Tosi P; Sonneveld P; Boccadoro M; Morgan G; Richardson P; Sezer O; Mateos MV; Cavo M; Joshua D; Turesson I; Chen W; Shimizu K; Powles R; Rajkumar SV; Durie BG;
Leukemia; 2009 Feb; 23(2):215-24. PubMed ID: 19020545
[TBL] [Abstract][Full Text] [Related]
19. Inter-assay variability in automated serum free light chain assays and their use in the clinical laboratory.
Caponi L; Romiti N; Koni E; Fiore AD; Paolicchi A; Franzini M
Crit Rev Clin Lab Sci; 2020 Mar; 57(2):73-85. PubMed ID: 31612753
[TBL] [Abstract][Full Text] [Related]
20. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis.
Kumar SK; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Zeldenrust SR; Tan T; Sinha S; Leung N; Kyle RA; Rajkumar SV; Gertz MA
Am J Hematol; 2011 Mar; 86(3):251-5. PubMed ID: 21328431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
